StockData

Immunocore vs Krystal Biotech

IMCR and KRYS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IMCR and KRYS compare

Krystal Biotech is the larger company, worth 6.2 times as much as Immunocore ($8.8B against $1.4B).

Krystal Biotech grew revenue faster over the last twelve months (22.6% versus 21.0% for Immunocore).

Krystal Biotech keeps more of each dollar of sales as profit, with a net margin of 54.8% compared with −4.2% at Immunocore.

Krystal Biotech scores higher on the StockData Score (11 against 7 for Immunocore), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIMCRKRYS
Size and price
Market cap$1.4B$8.8B
Share price$27.81$298.55
Change, 1 year−22.6%44.8%
Change, 5 years−23.6%650%
Beta (5Y)0.191.01
Employees524295
StockData Score
Total score711 (better)
Valuation score11
Growth score2 (better)1
Performance score33
Health score16 (better)
Dividend score00
Valuation
P/E–37.4×
P/S3.3× (better)20.1×
P/B3.4× (better)6.5×
EV/EBITDA–40.4×
P/FCF–34.3×
FCF yield−2.9%2.9% (better)
Fair value$32.29$195.99
Margin of safety13.9% (better)−52.3%
Growth
Revenue growth (TTM)21.0%22.6% (better)
Net income growth (TTM)–64.6%
EPS growth (TTM)–62.2%
Profitability
Gross margin98.9%–
Operating margin−5.2%44.9% (better)
Net margin−4.2%54.8% (better)
FCF margin−9.6%58.5% (better)
Return on equity−4.5%20.1% (better)
Return on invested capital–45.3%
Financial health
Debt / equity–0.00
Interest coverage−1.8×–
Current ratio4.478.32 (better)
Altman Z-score1.4039.06 (better)
Piotroski F-score36 (better)
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%102%
Held by insiders15.5%17.1%
Insider net buying, 12 months−$1.9M (better)−$105M
Short interest, % of float–12.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.